Polycystic ovary syndrome (PCOS) and menstrual disorders are prevalent gynecological conditions affecting a significant number of women worldwide. The management of these conditions often involves the prescription of various drugs to alleviate symptoms and improve overall reproductive health. However, the use of medications in these conditions is not without risks, as adverse drug reactions (ADRs) may occur, posing potential challenges to patient safety and treatment outcomes. This study aimed to investigate the drugs prescribed and document adverse drug reactions associated with PCOS and menstrual disorders in the Gynecology Department at IIMS&R Integral University, Lucknow, India. The study adopted a prospective observational design, analyzing medical records of female patients diagnosed with PCOS and menstrual disorders who sought care at the Gynecology Department. Data on prescribed drugs, dosage, duration of treatment, and patient demographics was extracted from electronic health records. Adverse drug reactions were identified through systematic review of patients\' medical records, specifically focusing on any reported symptoms, complications, or changes in treatment regimens due to drug-related issues. All identified ADRs were assessed for severity, causality, and preventability following standard pharmacovigilance guidelines. The findings of this study have the potential to improve patient safety, enhance the quality of care, and contribute to evidence-based practices in the management of PCOS and menstrual disorders. Moreover, it can serve as a foundation for future research endeavors aimed at exploring alternative treatment strategies or novel therapeutics for these gynecological conditions.